5-FU	5-fluorouracil
a/m	advanced or metastatic
a/mBC	advanced or metastatic breast cancer
A + AVD	brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine
ABVD	doxorubicin, bleomycin, vinblastine, and dacarbazine
ADCs	antibody–drug conjugates
AGAs	actionable genomic alterations
ALL	acute lymphoblastic leukemia
AML	acute myeloid leukemia
AN + AD	brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine
B-ALL	B-cell precursor acute lymphoblastic leukemia
B-NHL	B-cell non-Hodgkin lymphoma
BCBM	breast cancer brain metastases
BICR	blinded independent central review
CAPE	capecitabine
CAYA	children, adolescents, and young adults
cHL	classical Hodgkin lymphoma
CMR	complete molecular response
cORR	confirmed objective response rate
CR	complete response
DA-EPOCH-R	dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab
DAS	dasatinib
Dato-DXd	datopotamab deruxtecan
DDR	DNA damage response
DFS	disease-free survival
DHL/THL	double-hit and triple-hit lymphomas
DLBCL	diffuse large B-cell lymphoma
DLTs	dose-limiting toxicities
DOR	duration of response
EBC	early breast cancer
EC	endometrial cancer
EFS	event-free survival
ENKTL	extranodal NK/T-cell lymphoma
EOC	epithelial ovarian cancer
EOT	end of treatment
FDA	the United States Food and Drug Administration
FL	follicular lymphoma
FRα	folate receptor alpha
Gas	genomic alterations
GC	gastric cancer
GCB	germinal center B-cell-like
GCTs	germ cell tumors
GEA/GEJC	gastroesophageal adenocarcinoma/gastroesophageal junction cancer
GEJ	gastroesophageal junction
GO	gemtuzumab ozogamicin
GU	genitourinary
HER2+	HER2-positive
HER2e	HER2 overexpression
HER2m	HER2 mutations
HL	Hodgkin lymphoma
HR	hazard ratio
IBC	inflammatory breast cancer
ICIs	immune checkpoint inhibitors
ICR	independent central review
iDFS	invasive disease-free survival
InO	inotuzumab ozogamicin
IRC	Independent Review Committee
IV	intravenous
la/mBC	locally advanced or metastatic breast cancer
la/mUC	locally advanced or metastatic urothelial carcinoma
LBCL	large B-cell lymphoma
Len	lenalidomide
LT	loncastuximab tesirine
M-Pola	mosunetuzumab SC and polatuzumab vedotin
mAb	monoclonal antibody
mBC	metastatic breast cancer
mDOR	median duration of response
mGEAC	metastatic gastroesophageal adenocarcinoma
mini-Hyper-CVD	dose-reduced cyclophosphamide, vincristine, and dexamethasone
MIRV	mirvetuximab soravtansine
MMR	major molecular response
mNSCLC	metastatic NSCLC
mPFS	median progression-free survival
MRD	minimal residual disease
MTD	maximum tolerated dose
mUC	metastatic urothelial carcinoma
ND	newly diagnosed
NGS	next-generation sequencing
NHL	non-Hodgkin lymphoma
NR	not reached
NSCLC	non-small-cell lung cancer
ORR	objective response rates
OS	overall survival
pCR	pathologic complete response
PD-1	programmed cell Death protein-1
PDE4	phosphodiesterase-4
PFS	progression-free survival
Ph	Philadelphia chromosome
PMBL	primary mediastinal large B-cell lymphoma
Pola	polatuzumab vedotin
Pola-R-CHP	Pola, rituximab, cyclophosphamide, doxorubicin, and prednisone
Pola-ZR	Pola, zanubrutinib, and rituximab
Pola-BR	Pola, bendamustine and rituximab
POMP	6-mercaptopurine, vincristine, methotrexate, and prednisone
PR	partial response
PROC	platinum-resistant ovarian cancer
PSOC	platinum-sensitive ovarian cancer
PTCL	peripheral T-cell lymphoma
R-CHOP	rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
R-CHP	rituximab, cyclophosphamide, doxorubicin, and prednisone
R-GemOx	rituximab, gemcitabine, and oxaliplatin
r/mCC	recurrent or metastatic cervical cancer
R/R	relapsed or refractory
R	rituximab
RANO-BM	response assessment in neuro-oncology-brain metastases
RDE	recommended dose for expansion
RFS	relapse-free survival
RP2D	recommended phase II dose
SC	subcutaneous
SCT	stem cell transplantation
SOS	sinusoidal obstruction syndrome
T-DM1	trastuzumab emtansine
T-DXd	trastuzumab deruxtecan
Teliso-V	telisotuzumab vedotin
TNBC	triple-negative breast cancer
Ven	venetoclax